Synthesis and Characterization of Poly(ethylene glycol)−Glutathione Conjugate Self-Assembled Nanoparticles for Antioxidant Delivery

Williams, Sharlene R.; Lepene, Benjamin; Thatcher, Craig D.; Long, Timothy Edward

doi:10.1021/bm801058j

Cited by 69 publications

(45 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A combination of resveratrol and curcumin was shown to reduce prostate cancer in a mouse model by liposomal delivery [43]. GSH and polyethylene diacrylate (PEGDA) oligomers created liposome-like spherical self-assembly nanoparticles which have been shown to protect cells from oxidative stress in vitro [44]. …”

Section: Nonpolymeric Carriersmentioning

confidence: 99%

Nanocarriers for Vascular Delivery of Antioxidants

et al. 2011

View full text Add to dashboard Cite

Antioxidant enzymes (AOEs) catalase and superoxide dismutase (SOD) detoxify harmful reactive oxygen species, but the therapeutic utility of AOEs is hindered by inadequate delivery. AOE modification by polyethylene glycol (PEG) and encapsulation in PEG-coated liposomes increases the AOE bioavailability and enhances protective effects in animal models. Pluronic-based micelles formed with AOEs show even more potent protective effects. Furthermore, polymeric nanocarriers (PNCs) based on PEG-copolymers protect encapsulated AOEs from proteolysis and improve delivery to the target cells, such as the endothelium lining the vascular lumen. Antibodies to endothelial determinants conjugated to AOEs or AOE carriers provide targeting and intracellular delivery. Targeted liposomes, protein conjugates and magnetic nanoparticles deliver AOEs to sites of vascular oxidative stress in the cardiovascular, pulmonary and nervous systems. Further advances in nanodevices for AOE delivery will provide a basis for the translation of this approach in the clinical domain.

show abstract

Section: Nonpolymeric Carriersmentioning

confidence: 99%

Nanocarriers for Vascular Delivery of Antioxidants

et al. 2011

View full text Add to dashboard Cite

show abstract

“…As an alternative to growth factor release by diffusion, NP can be designed for disintegration by chemical cleavage with compounds present in the physiological system. The disulfide-linked NPs, in this regard, is a good example for environment-responsive system (131). Despite good understanding of in vitro degradation of NPs, little effort has been exerted to probe in vivo degradation of NPs.…”

Section: Discussionmentioning

confidence: 99%

Nanoparticulate Systems for Growth Factor Delivery

2009

View full text Add to dashboard Cite

The field of nanotechnology, which aims to control and utilize matter generally in 1-100 nm range, has been at the forefront of pharmaceutical development. Nanoparticulate delivery systems, with their potential to control drug release profiles, prolonging the presence of drugs in circulation, and to target drugs to a specific site, hold tremendous promise as delivery strategies for therapeutics. Growth factors are endogenous polypeptides that initiate intracellular signals to regulate cellular activities, such as proliferation, migration and differentiation. With improved understanding of their roles in physiopathology and expansion of their availability through recombinant technologies, growth factors are becoming leading therapeutic candidates for tissue engineering approaches. However, the outcome of growth factor therapeutics largely depends on the mode of their delivery due to their rapid degradation in vivo, and non-specific distribution after systemic administration. In order to overcome these impediments, nanoparticulate delivery systems are being harnessed for spatiotemporal controlled delivery of growth factors. This review presents recent advances and some disadvantages of various nanoparticulate systems designed for effective intact growth factor delivery. The therapeutic applications of growth factors delivered by such systems are reviewed, especially for bone, skin and nerve regeneration as well as angiogenesis. Finally, future challenges and directions in the field are presented in addition to the current limitations.

show abstract

“…Inadequate delivery has long been suspected, and numerous NCs have been proposed. For example, vitamin E, glutathione (GSH), ascorbic acid, and other antioxidants have been conjugated to carriers based on synthetic polymers of poly(acrylic acid) or PEG-poly(methyl methacrylate) as well as natural protein carriers (e.g., gelatin), and these formulations protected cells against oxidative stress in vitro (81, 82). More recently, NCs composed of condensed or polymerized antioxidant materials (e.g., tocopherol) have also been reported (83).…”

Section: Nanocarrier-mediated Delivery Of Anti-inflammatory Agentsmentioning

confidence: 99%

“…Hydrophobic antioxidants including vitamin E, ubiquinones, retinoids, carotenoids, flavonoids, and butylated hydroxytoluene have been incorporated within the liposomal bilayer to improve their solubility and provide protection for the drug (84, 85). The hydrophilic antioxidant, reduced GSH, was encapsulated in the aqueous volume of liposomes and liposome-like spherical self-assembled particles and was shown to protect cells from oxidative stress in vitro (82). N-acetylcysteine (NAC), a hydrophilic derivative of cysteine, has antioxidant activities and replenishes GSH in tissues.…”

Section: Nanocarrier-mediated Delivery Of Anti-inflammatory Agentsmentioning

confidence: 99%

Nanocarriers for Vascular Delivery of Anti-Inflammatory Agents

Howard

Hood

Zern

et al. 2014

Annu. Rev. Pharmacol. Toxicol.

View full text Add to dashboard Cite

There is a need for improved treatment of acute vascular inflammation in conditions such as ischemia-reperfusion injury, acute lung injury, sepsis, and stroke. The vascular endothelium represents an important therapeutic target in these conditions. Furthermore, some anti-inflammatory agents (AIAs) (e.g., biotherapeutics) require precise delivery into subcellular compartments. In theory, optimized delivery to the desired site of action may improve the effects and enable new mechanisms of action of these AIAs. Diverse nanocarriers (NCs) and strategies for targeting them to endothelial cells have been designed and explored for this purpose. Studies in animal models suggest that delivery of AIAs using NCs may provide potent and specific molecular interventions in inflammatory pathways. However, the industrial development and clinical translation of complex NC-AIA formulations are challenging. Rigorous analysis of therapeutic/side effect and benefit/cost ratios is necessary to identify and optimize the approaches that may find clinical utility in the management of acute inflammation.

show abstract

Synthesis and Characterization of Poly(ethylene glycol)−Glutathione Conjugate Self-Assembled Nanoparticles for Antioxidant Delivery

Cited by 69 publications

References 52 publications

Nanocarriers for Vascular Delivery of Antioxidants

Nanocarriers for Vascular Delivery of Antioxidants

Nanoparticulate Systems for Growth Factor Delivery

Nanocarriers for Vascular Delivery of Anti-Inflammatory Agents

Contact Info

Product

Resources

About